Malaria drug is biggest hope against coronavirus: Novartis CEO

Swiss newspaper SonntagsZeitung reported that Novartis Chief Executive Vas Narasimhan said his Sandoz generics unit’s malaria, lupus and arthritis drug hydroxychloroquine is the company’s biggest hope against the coronavirus.

Novartis has pledged to donate 130 million doses and is also supporting clinical trials needed before the medicine, which US President Donald Trump also has been promoting, can be approved for use against the coronavirus.

Companies including Bayer and Teva have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences is testing its experimental drug remdesivir against coronavirus.

Narasimhan told the newspaper that “Pre-clinical studies in animals as well as the first data from clinical studies show that hydroxychloroquine kills the coronavirus, We’re working with Swiss hospitals on possible treatment protocols for the clinical use of the drug, but it’s too early to say anything definitively. The company is currently looking for additional active drug ingredients to make more hydroxychloroquine, should clinical trials be successful, he further added

Narasimhan said, three other Novartis drugs – Jakavi for cancer, multiple sclerosis drug Gilenya and fever drug Ilaris – are being studied for their effect on complications related to COVID-19, the newspaper reported. This follows separate efforts to re-purpose drugs made by companies including Roche and Sanofi to treat complications related to the disease.

  • Related Posts

    • Pharma
    • July 22, 2025
    • 149 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    • Pharma
    • July 16, 2025
    • 576 views
    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug